Pharmacy ops up chain’s health cred out West
Raley’s responded to heightened awareness of flu in its California and Nevada markets by moving up its seasonal vaccination program to Sept. 16 this year, and launching an H1N1 effort at select stores on Jan. 12.
The company has built an extensive flu vaccination program over 15 years that includes programs that encourage employee vaccinations and ensure all its customers have access to flu shots. “In 2009, we hosted seasonal flu shot clinics inside the majority of our stores—even those without pharmacy departments—by working with Health Tech Mobile and Renown Health Group,” said Amy Davis, a company spokeswoman. “Demonstrating our company’s commitment to helping employees maintain healthy lifestyles, Raley’s once again offered free seasonal flu vaccinations to every employee who chose to get one.”
Headquarters: West Sacramento, Calif.2009 sales: $3.54 billion% change vs. 2008: 1%No. of stores: 134No. of stores with Rx: 109Avg. store size: 50,000 sq. ft.Rx sales: $318 million% of sales from Rx: 9%Sales per store: $26.4 million
Source: Company reports
Raley’s has developed a range of pharmacy operations designed to bolster its credentials as a healthy-living resource in the community. It promotes natural and organic foods, as well as nutritious eating with advice from its registered dietician Earline Griffith. It also has offered health screenings as part of store openings.
Schnucks’ O’Brien to serve on Department of Agriculture advisory committee
ST. LOUIS An executive from Schnuck Markets will serve on an advisory committee of the Department of Agriculture, Schnucks said this week.
Agriculture secretary Tom Vilsack announced that Schnucks VP produce and floral Mike O’Brien would be one of 25 people appointed to a two-year term on the USDA’s Fruit and Vegetable Industry Advisory Committee. O’Brien is also vice chairman of the Produce Marketing Association.
“I am honred to represent Schnuck Markets and the retail produce industry as a member of this committee,” O’Brien said. “I am looking forward to the opportunity to contribute and to make a difference for families across the nation.”
The committee, originally chartered in 2001, advises the secretary of agriculture on industry issues related to fruits and vegetables.
Gilead commences phase 3 trial for single-tablet HIV treatment
FOSTER CITY, Calif. Gilead Sciences has started a late-stage clinical trial of an investigational 4-in-1 treatment for HIV, the drug maker said.
Gilead announced the initiation of a phase 3 trial of its “Quad” HIV drug, a single-tablet treatment that combines elvitegravir, cobicistat, emtricitabine and tenofovir disoproxil fumarate. The study will compare the Quad regimen with the standard of care among adults with HIV-1 who have not taken antiretroviral treatments. The company is also investigating cobicistat as a standalone boosting agent for antiretroviral drugs.
“We are pleased to announce that the Quad phase 3 clinical program is underway,” Gilead EVP research and development and chief scientific officer Norbert Bischofberger said. “Efficacy and safety results from the phase 2 study suggest that the Quad may represent an important new option for patients with HIV.”